This invention relates to peptides,nucleic acids and cells for use in immunotherapy methods. Specifically,this invention is related to cancer immunotherapy. This invention is additionally related to tumour-related peptide T-cell sites (cytotoxic T lymphocytes (CTL),isolated or in combination with other tumour-related peptides,which act as active pharmaceutical components of vaccine formulations that trigger anticancer immune responses. This invention relates to 30-peptide sequences andtheir mutations from HLA Class I and II molecules of human cancer cells that can be used in vaccine combinations to induce anticancer immune responses.
展开▼